Nitrous Oxide Emissions

End of project reportNitrous oxide (N2O) is one of the three most important greenhouse gases (GHG). Nitrous oxide emissions currently account for approximately one third of GHG emissions from agriculture in Ireland. Emissions of N2O arise naturally from soil sources and from the application of nitrogen (N) in the form of N fertilizers and N in dung and urine deposition by grazing animals at pasture. Nitrous oxide emission measurements were conducted at three different scales. Firstly, a large-scale field experiment was undertaken to compare emission rates from a pasture receiving three different rates of N fertilizer application and to identify the effects of controlling variables over a two-year period. Variation in emission rates was large both within and between years. Two contrasting climatic years were identified. The cooler and wetter conditions in year 1 gave rise to considerably lower emission levels than the warmer and drier year 2. However, in both years, peak emissions were associated with fertilizer N applications coincident with rainfall events in the summer months. A small-plot study was conducted to identify the individual and combined effects of fertilizer, dung and urine applications to grassland. Treatment effects were however, difficult to obtain due to the overriding effects of environmental variables. Thirdly, through the use of a small-scale mini-lysimeter study, the diurnal nature of N2O emission rates was identified for two distinct periods during the year. The occurrence of a diurnal pattern has important implications for the identification of a measurement period during the day which is representative of the true daily flux. The research presented aims to identify the nature and magnitude of N2O emissions and the factors which affect emission rates from a grassland in Ireland. Further work is required to integrate the effects of different soil types and contrasting climatic regimes across soil types on N2O emissions.Environmental Protection Agenc

Effect of Iron Availability on Expression of the Bradyrhizobium Japonicum hemA Gene.

Bradyrhizobium japonicum produces delta-aminolevulinic acid, the universal precursor of tetrapyrroles, in a reaction catalyzed by the product of the hemA gene. Expression of the B. japonicum hemA gene is affected by iron availability. Activity of a hemA-lacZ fusion is increased approximately threefold by iron, and RNA analysis indicates that iron regulation is at the level of mRNA accumulation. To our knowledge, this is the first example of an iron-regulated heme biosynthetic gene in prokaryotes

Overview of Human Factors and Habitability at NASA

This slide presentation reviews the ongoing work on human factors and habitability in the development of the Constellation Program. The focus of the work is on how equipment, spacecraft design, tools, procedures and nutrition be used to improve the health, safety and efficiency of the crewmembers. There are slides showing the components of the Constellation Program, and the conceptual designs of the Orion Crew module, the lunar lander, (i.e., Altair) the microgravity EVA suit, and the lunar surface EVA suit, the lunar rover, and the lunar surface system infrastructure

Who Publishes in “Predatory” Journals?

Many open access journals have a reputation for being of low quality and being dishonest with regard to peer review and publishing costs. Such journals are labeled “predatory” journals. This study examines author profiles for some of these “predatory” journals as well as for groups of more well-recognized open access journals. We collect and analyze the publication record, citation count, and geographic location of authors from the various groups of journals. Statistical analyses verify that each group of journals has a distinct author population. Those who publish in “predatory” journals are, for the most part, young and inexperienced researchers from developing countries. We believe that economic and sociocultural conditions in these developing countries have contributed to the differences found in authorship between “predatory” and “nonpredatory” journals

Novel mutations expand the clinical spectrum of DYNC1H1-associated spinal muscular atrophy

OBJECTIVE To expand the clinical phenotype of autosomal dominant congenital spinal muscular atrophy with lower extremity predominance (SMA-LED) due to mutations in the dynein, cytoplasmic 1, heavy chain 1 (DYNC1H1) gene. METHODS Patients with a phenotype suggestive of a motor, non-length-dependent neuronopathy predominantly affecting the lower limbs were identified at participating neuromuscular centers and referred for targeted sequencing of DYNC1H1. RESULTS We report a cohort of 30 cases of SMA-LED from 16 families, carrying mutations in the tail and motor domains of DYNC1H1, including 10 novel mutations. These patients are characterized by congenital or childhood-onset lower limb wasting and weakness frequently associated with cognitive impairment. The clinical severity is variable, ranging from generalized arthrogryposis and inability to ambulate to exclusive and mild lower limb weakness. In many individuals with cognitive impairment (9/30 had cognitive impairment) who underwent brain MRI, there was an underlying structural malformation resulting in polymicrogyric appearance. The lower limb muscle MRI shows a distinctive pattern suggestive of denervation characterized by sparing and relative hypertrophy of the adductor longus and semitendinosus muscles at the thigh level, and diffuse involvement with relative sparing of the anterior-medial muscles at the calf level. Proximal muscle histopathology did not always show classic neurogenic features. CONCLUSION Our report expands the clinical spectrum of DYNC1H1-related SMA-LED to include generalized arthrogryposis. In addition, we report that the neurogenic peripheral pathology and the CNS neuronal migration defects are often associated, reinforcing the importance of DYNC1H1 in both central and peripheral neuronal functions

Tumor and serum DNA methylation in women receiving preoperative chemotherapy with or without vorinostat in TBCRC008

BACKGROUND: Methylated gene markers have shown promise in predicting breast cancer outcomes and treatment response. We evaluated whether baseline and changes in tissue and serum methylation levels would predict pathological complete response (pCR) in patients with HER2-negative early breast cancer undergoing preoperative chemotherapy. METHODS: The TBCRC008 trial investigated pCR following 12 weeks of preoperative carboplatin and albumin-bound paclitaxel + vorinostat/placebo (n = 62). We measured methylation of a 10-gene panel by quantitative multiplex methylation-specific polymerase chain reaction and expressed results as cumulative methylation index (CMI). We evaluated association between CMI level [baseline, day 15 (D15), and change] and pCR using univariate and multivariable logistic regression models controlling for treatment and hormone receptor (HR) status, and performed exploratory subgroup analyses. RESULTS: In univariate analysis, one log unit increase in tissue CMI levels at D15 was associated with 40% lower chance of obtaining pCR (odds ratio, OR 0.60, 95% CI 0.37-0.97; p = 0.037). Subgroup analyses suggested a significant association between tissue D15 CMI levels and pCR in vorinostat-treated [OR 0.44 (0.20, 0.93), p = 0.03], but not placebo-treated patients. CONCLUSION: In this study investigating the predictive roles of tissue and serum CMI levels in patients with early breast cancer for the first time, we demonstrate that high D15 tissue CMI levels may predict poor response. Larger studies and improved analytical procedures to detect methylated gene markers in early stage breast cancer are needed. TBCRC008 is registered on ClinicalTrials.gov (NCT00616967)

Clinical trials of health information technology interventions intended for patient use: Unique issues and considerations

BACKGROUND: Despite the proliferation of health information technology (IT) interventions, descriptions of the unique considerations for conducting randomized trials of health IT interventions intended for patient use are lacking. PURPOSE: Our purpose is to describe the protocol to evaluate Pocket PATH (Personal Assistant for Tracking Health), a novel health IT intervention, as an exemplar of how to address issues that may be unique to a randomized controlled trial (RCT) to evaluate health IT intended for patient use. METHODS: An overview of the study protocol is presented. Unique considerations for health IT intervention trials and strategies are described to maintain equipoise, to monitor data safety and intervention fidelity, and to keep pace with changing technology during such trials. LESSONS LEARNED: The sovereignty granted to technology, the rapid pace of changes in technology, ubiquitous use in health care, and obligation to maintain the safety of research participants challenge researchers to address these issues in ways that maintain the integrity of intervention trials designed to evaluate the impact of health IT interventions intended for patient use. CONCLUSIONS: Our experience evaluating the efficacy of Pocket PATH may provide practical guidance to investigators about how to comply with established procedures for conducting RCTs and include strategies to address the unique issues associated with the evaluation of health IT for patient use